Kastle Therapeutics LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-07-16
- Employees
- 11
- Market Cap
- -
Clinical Trials
18
Active:0
Completed:18
Trial Phases
3 Phases
Phase 1:5
Phase 2:7
Phase 3:6
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Phase 2
7 (38.9%)Phase 3
6 (33.3%)Phase 1
5 (27.8%)A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
Phase 3
Completed
- Conditions
- Heterozygous FamilialHypercholesterolemia
- Interventions
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 309
- Registration Number
- NCT01475825
Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT01414881
- Locations
- 🇺🇸
Columbia-Presbyterian Medical Center, MS Care Center, New York, New York, United States
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT01299298
- Locations
- 🇩🇪
FOCUS Clinical Drug Development GmbH, Stresemannallee 6, Neuss, Germany
A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT01133366
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-03-22
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT01090661
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found